Eloxx Pharmaceuticals (ELOX) 10-Q 6 May 22 2022 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2022	May 03, 2022
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2022
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q1
Trading Symbol	ELOX
Entity Registrant Name	ELOXX PHARMACEUTICALS, INC.
Entity Central Index Key	0001035354
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Common Stock, Shares Outstanding		86,653,089
Entity Small Business	true
Entity Emerging Growth Company	false
Entity File Number	001-31326
Entity Tax Identification Number	84-1368850
Entity Address, Address Line One	480 Arsenal Way
Entity Address, City or Town	Watertown
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	02472
City Area Code	781
Local Phone Number	577-5300
Entity Incorporation, State or Country Code	DE
Entity Shell Company	false
Entity Current Reporting Status	Yes
Title of 12(b) Security	Common Stock, $0.01 par value per share
Entity Interactive Data Current	Yes
Security Exchange Name	NASDAQ
Document Quarterly Report	true
Document Transition Report	false

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 39,768	$ 42,268
Restricted cash	297	299
Prepaid expenses and other current assets	2,082	913
Total current assets	42,147	43,480
Property and equipment, net	206	216
Operating lease right-of-use asset	1,265	1,443
Total assets	43,618	45,139
Current liabilities:
Accounts payable	2,903	1,379
Accrued expenses	4,631	4,196
Advances from collaboration partners	10,723	3,723
Derivative liabilities	270
Current portion of operating lease liability	647	657
Total current liabilities	19,174	9,955
Long-term debt	12,120	11,996
Operating lease liability	638	804
Total liabilities	31,932	22,755
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $0.01 par value per share, 5,000,000 shares authorized, no shares issued or outstanding as of March 31, 2022 and December 31, 2021
Common stock, $0.01 par value per share, 500,000,000 shares authorized, 87,074,455 and 87,071,324 shares issued and 86,653,089 and 86,649,958 shares outstanding as of March 31, 2022 and December 31, 2021, respectively	871	871
Common stock in treasury, at cost, 421,366 shares as of March 31, 2022 and December 31, 2021	(2,190)	(2,190)
Additional paid-in capital	262,948	262,026
Accumulated deficit	(249,943)	(238,323)
Total stockholders’ equity	11,686	22,384
Total liabilities and stockholders’ equity	$ 43,618	$ 45,139

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2022	Dec. 31, 2021
Statement Of Financial Position [Abstract]
Preferred stock, par value	$ 0.01	$ 0.01
Preferred Stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred Stock, shares outstanding	0	0
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	500,000,000	500,000,000
Common stock, shares issued	87,074,455	87,071,324
Common stock, shares outstanding	86,653,089	86,649,958
Common stock, treasury shares	421,366	421,366

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Operating expenses:
Research and development	$ 7,899	$ 4,073
General and administrative	3,054	4,341
Total operating expenses	10,953	8,414
Loss from operations	(10,953)	(8,414)
Other expense, net	667	280
Net loss and comprehensive loss	$ (11,620)	$ (8,694)
Net loss per share, basic and diluted	$ (0.13)	$ (0.22)
Weighted average number of shares of common stock used in computing net loss per share, basic and diluted	86,651,036	40,180,131

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Cash flows from operating activities:
Net loss	$ (11,620)	$ (8,694)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation	922	1,308
Depreciation	21	16
Amortization of operating lease right-of-use asset	177	132
Amortization of debt discount	124	110
Change in fair value of derivative liabilities	270
Changes in operating assets and liabilities:
Prepaid expenses and other assets	(1,169)	(460)
Accounts payable	1,525	4
Accrued expenses	434	31
Operating lease liabilities	(175)	(132)
Net cash used in operating activities	(9,491)	(7,685)
Cash flows from investing activities:
Purchase of property and equipment	(11)
Net cash (used in) provided by investing activities	(11)
Cash flows from financing activities:
Repayment of term loan principal		(1,250)
Proceeds from advances from collaboration partners	7,000	2,606
Payment for settlement of taxes upon vesting of restricted stock units		(94)
Net cash provided by financing activities	7,000	1,262
Increase (decrease) in cash, cash equivalents and restricted cash	(2,502)	(6,423)
Cash, cash equivalents and restricted cash at the beginning of the period	42,567	24,724
Cash, cash equivalents and restricted cash at the end of the period	40,065	18,301
Reconciliation of cash, cash equivalents and restricted cash to condensed consolidated balance sheets:
Cash and cash equivalents	39,768	18,247
Restricted cash	297	54
Cash, cash equivalents and restricted cash at the end of the period	40,065	18,301
Supplemental disclosure of cash flow activities:
Cash paid for interest	$ 297	$ 144

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Treasury stock [Member]	Accumulated deficit [Member]
Balance at Dec. 31, 2020	$ 10,230	$ 404	$ 183,250	$ (1,828)	$ (171,596)
Balance, shares at Dec. 31, 2020		40,157,187		(193,735)
Vesting of restricted stock units	(94)			$ (94)
Vesting of restricted stock units, shares		57,687		(23,883)
Stock-based compensation expense	1,308		1,308
Net loss	(8,694)				(8,694)
Balance at Mar. 31, 2021	2,750	$ 404	184,558	$ (1,922)	(180,290)
Balance, shares at Mar. 31, 2021		40,214,874		(217,618)
Balance at Dec. 31, 2021	$ 22,384	$ 871	262,026	$ (2,190)	(238,323)
Balance, shares at Dec. 31, 2021	86,649,958	86,649,958		(421,366)
Vesting of restricted stock units, shares		3,131
Stock-based compensation expense	$ 922		922
Net loss	(11,620)				(11,620)
Balance at Mar. 31, 2022	$ 11,686	$ 871	$ 262,948	$ (2,190)	$ (249,943)
Balance, shares at Mar. 31, 2022	86,653,089	86,653,089		(421,366)

Nature of the Business

Nature of the Business	3 Months Ended
	Mar. 31, 2022
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Nature of the Business	1. Nature of the Business Eloxx Pharmaceuticals, Inc., together with its subsidiaries (collectively “Eloxx” or the “Company”), is a clinical-stage biopharmaceutical company engaged in the science of ribosomal modulation. The Company is developing novel small molecule drug candidates from its library of unique Ribosome Modulating Agents (“RMAs”) and Eukaryotic Ribosomal Selective glycosides (“ERSGs”), for the treatment of a subset of rare and ultra-rare diseases and cancers characterized by genetic mutations that cause defects in protein translation. Specifically, the Company is targeting premature stop codon mutations and ribosomal mutations. Premature stop codons are point mutations that disrupt the stability of the impacted messenger RNA (mRNA) and the protein synthesis from that mRNA. Additionally, certain mutations of the ribosome disrupt normal protein translation and are drivers of a subset of cancers. On April 1, 2021, the Company acquired Zikani Therapeutics, Inc. (“Zikani”), a preclinical stage biopharmaceutical company engaged in the science of ribosome modulation, leveraging its innovative TURBO-ZM TM chemistry technology platform to develop novel ribosome modulating agents (“RMAs”). The TURBO-ZM TM platform is designed to enable rapid synthesis of novel macrolides that can be optimized to modulate the human, bacterial or viral ribosomes to treat rare diseases and cancers with certain ribonucleic acid (“RNA”) and ribosomal mutations. The Company is headquartered in Watertown, Massachusetts, with additional operations in Israel and Australia. Liquidity and Going Concern The Company has a history of net losses and negative cash flows from operating activities since inception, and as of March 31, 2022, had an accumulated deficit of $249.9 million. The Company expects to continue to incur net losses and use cash in its operations for the foreseeable future. The Company has not generated revenue from the sale of any product or service and does not expect to generate significant sales revenue unless and until it obtains marketing approval for and commercializes one or more of its product candidates currently in development. Successful transition to profitable operations is dependent upon achieving a level of revenue adequate to support the Company’s cost structure. The Company has financed its operations primarily from the sale of equity securities and to a lesser extent, loans and grants. The Company may never achieve profitability, and unless and until it does, the Company will continue to need to raise additional capital to fund its operations. In addition, as disclosed in Note 6, in September 2021, the Company entered into a Loan and Security Agreement for an aggregate principal amount of $30.0 million of which $12.5 million had been funded as of March 31, 2022. The term loan contains customary affirmative and negative covenants, which among others further described in Note 6, require the Company to maintain at all times a minimum qualified cash balance equaling amounts ranging from $6.3 million to $10.0 million plus qualified accounts payable (as defined). As of March 31, 2022, the Company was in compliance with all debt covenants. However, the inherent uncertainties described above may impact the Company’s ability to remain in compliance with these covenants over the next twelve months. If the Company breaches its financial covenants and fails to secure a waiver or forbearance from the third-party lender, such breach or failure could accelerate the repayment of the outstanding borrowings under the Credit Agreement or the exercise of other rights or remedies the third-party lender may have under applicable law. No assurance can be provided a waiver or forbearance will be granted or the outstanding borrowings under the Loan and Security Agreement, will be successfully refinanced on terms that are acceptable to the Company. The Company believes that its cash and cash equivalents of $39.8 million at March 31, 2022 will not be sufficient to maintain its current and planned operations for at least the next twelve months following the filing of this Quarterly Report on Form 10-Q. The accompanying condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and settlement of liabilities in the normal course of business. However, based on the Company’s current working capital, anticipated operating expenses and net losses and the uncertainties surrounding its ability to raise additional capital as needed, as discussed below, the Company believes that these conditions, in aggregate, raise substantial doubt about its ability to continue as a going concern for one year after the date these consolidated financial statements are issued. Management intends to fund future operations through private or public debt or equity financing transactions and may seek additional capital through arrangements with strategic partners or from other sources. The availability of sufficient funding to alleviate the conditions that raise substantial doubt are not within management’s control and cannot be assessed as being probable of occurring. If the Company is unable to obtain adequate financing, it will evaluate options which may include reducing or deferring operating expenses, which may have a material adverse effect on the Company’s operations and future prospects.

Basis of Presentation and Signi

Basis of Presentation and Significant Accounting Policies	3 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
Basis of Presentation and Significant Accounting Policies	2. Basis of Presentation and Significant Accounting Policies The Company has prepared the accompanying unaudited interim condensed consolidated financial statements in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Updates (“ASU”) promulgated by the Financial Accounting Standards Board (“FASB”). These interim condensed consolidated financial statements, in the opinion of management, reflect all normal recurring adjustments necessary for a fair presentation of the Company’s financial position, results of operations, and cash flows for the interim periods ended March 31, 2022 and 2021. Certain information and footnote disclosures normally included in the Company’s annual consolidated financial statements have been condensed or omitted, as permitted by such rules and regulations. These interim consolidated financial statements, in the opinion of management, reflect all normal recurring adjustments necessary for a fair presentation of the Company’s financial position, results of operations, and cash flows for the interim periods ended March 31, 2022 and 2021. The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full year. These interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements as of and for the year ended December 31, 2021, and the notes thereto, which are included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021, filed with the U.S. Securities and Exchange Commission (the “SEC”) on March 30, 2022 (the “2021 Annual Report”). The significant accounting policies used in the preparation of these condensed consolidated financial statements are consistent with those described in the Company’s audited consolidated financial statements as of and for the year ended December 31, 2021 and the notes thereto in the Company’s 2021 Annual Report. Recent Accounting Pronouncements Although the FASB has issued several ASUs for which adoption dates are pending, the Company does not expect any to have any impacts on its consolidated financial statements.

Prepaid Expenses and Other Curr

Prepaid Expenses and Other Current Assets	3 Months Ended
	Mar. 31, 2022
Prepaid And Other Current Assets [Abstract]
Prepaid Expenses and Other Current Assets	3. Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets consisted of the following (in thousands): March 31, 2022 December 31, 2021 Research and development $ 415 $ 413 Insurance 1,065 123 Other 602 377 Total $ 2,082 $ 913

Property and Equipment

Property and Equipment	3 Months Ended
	Mar. 31, 2022
Property Plant And Equipment [Abstract]
Property and Equipment	4. Property and Equipment Property and equipment, net consisted of the following (in thousands): March 31, 2022 December 31, 2021 Computers and software $ 31 $ 31 Office furniture and equipment 27 27 Laboratory equipment 221 221 Leasehold improvements 88 88 Assets in progress 31 20 398 387 Less accumulated depreciation (192 ) (171 ) Property and equipment, net $ 206 $ 216 Depreciation expense was $21 thousand and $16 thousand for the three months ended March 31, 2022 and 2021, respectively.

Accrued Expenses

Accrued Expenses	3 Months Ended
	Mar. 31, 2022
Payables And Accruals [Abstract]
Accrued Expenses	5. Accrued Expenses Accrued expenses consisted of the following (in thousands): March 31, 2022 December 31, 2021 Research and development expenses $ 3,374 $ 1,849 Payroll other employee-related expenses 528 1,615 Professional services 380 489 Other 245 141 Interest on debt 104 102 Total $ 4,631 $ 4,196

Debt

Debt	3 Months Ended
	Mar. 31, 2022
Debt Disclosure [Abstract]
Debt	6. Debt Hercules Term Loan On September 30, 2021, the Company entered into a Loan and Security Agreement, dated as of September 30, 2021 (the “Hercules Loan Agreement”) with Hercules Capital, Inc. (“Hercules” or the “Lender”). The Lender extended term loans in an aggregate principal amount of up to $30.0 million, comprised of (i) a tranche 1 advance of $12.5 million (the “Tranche 1 Advance”), (ii) a tranche 2 advance of $7.5 million (the “Tranche 2 Advance”) and (iii) a tranche 3 advance of $10.0 million (the “Tranche 3 Advance”) (collectively, the “Term Loan Advances”). The Tranche 1 Advance under the Loan Agreement was funded on September 30, 2021. The Tranche 2 Advance is available at the Company’s election after the occurrence of certain milestone events relating to data from the clinical trials. The Tranche 2 Advance will remain available for funding until August 15, 2022. The Tranche 3 Advance is available subject to approval by the Lenders’ investment committee in its sole discretion. The Tranche 3 Advance will remain available for funding until, initially, April 1, 2023, and (i) upon the occurrence of certain milestone events relating to the Company’s receipt of net cash proceeds, October 1, 2023, and (ii) upon the occurrence of certain milestone events relating to the Company’s receipt of net cash proceeds and certain milestone events relating to data from the clinical trials, April 1, 2024. As security for its obligations, the Company granted Hercules a continuing security interest in substantially all of the assets of the Company, subject to certain customary exceptions, including for intellectual property. Any outstanding principal on the Term Loan Advances will accrue interest at a floating rate equal to the greater of (i) 9.50% per annum and (ii) the sum of 6.25% plus the prime rate, as published in The Wall Street Journal . On September 30, 2021, the interest rate was 9.5%. Interest payments are payable monthly following the funding of a Term Loan Advance. The Company may prepay the outstanding principal amount of the Term Loan Advances at any time (in whole, but not in part), plus accrued and unpaid interest and a prepayment premium equal to (i) 3% of the principal amount outstanding if prepaid on or prior to the first anniversary of the date of Loan Agreement, (ii) 2% of the principal amount outstanding if prepaid after the first anniversary the date of Hercules Loan Agreement but on or prior to the second anniversary of the date of Hercules Loan Agreement, and (iii) 1% of the principal amount outstanding if prepaid after the second anniversary of the date of Hercules Loan Agreement but on or prior to the Maturity Date. The Hercules Loan Agreement contains customary affirmative and negative covenants which, among other things, requires the Company to maintain at all times a minimum qualified cash balance equaling amounts ranging from $6.3 million to $10.0 million plus qualified accounts payable (as defined) and limits the Company’s ability to (i) incur additional indebtedness, (ii) pay dividends or make certain distributions, (iii) dispose of its assets, grant liens or encumber its assets or (iv) fundamentally alter the nature of its business. These covenants are subject to a number of exceptions and qualifications. The Company was in compliance with all debt covenants at March 31, 2022. The Hercules Loan Agreement also contains customary events of default, including the Company’s failure to make any principal or interest payments when due, the occurrence of certain bankruptcy or insolvency events or a breach of the covenants. Upon the occurrence of an event of default, Hercules may, among other things, accelerate the Company’s obligations under the Hercules Loan Agreement. As of March 31, 2022, the carrying value of the outstanding loan consists of $12.5 million in principal less an unamortized debt discount of $1.2 million. The debt issuance costs and the final maturity payment of $0.8 million, have been recorded as a debt discount which are being accreted to interest expense through the maturity date of the loan. Interest expense relating to the loan for the three months ended March 31, 2022 and 2021 was $0.4 million and $0, respectively. Interest expense is calculated using the effective interest method and is inclusive of non-cash amortization of the debt discount. At March 31, 2022, the effective interest rate was 15.25%. SVB Term Loan On January 30, 2019, the Company entered into a Loan and Security Agreement (the “Loan Agreement”) in the amount of $15.0 million with Silicon Valley Bank (“SVB”) and WestRiver Innovation Lending Fund VIII, L.P. (“WestRiver”, and together with SVB, the “Lenders”). Outstanding principal on the loan accrues interest at a floating rate equal to the greater of (i) 5.25% per annum and (ii) the sum of 2.5% plus the prime rate, as published in the Wall Street Journal. Interest payments are payable monthly. On March 31, 2021, the interest rate was 5.75%. On September 30, 2021, in connection with the funding of the Hercules Term Loan Tranche 1 Advance and pursuant to a Payoff Letter dated September 30, 2021, the Company voluntarily repaid in full the carrying value of the outstanding loan consisting of $6.7 million of principal, a final maturity payment of $0.9 million, and early termination fees of $0.1 million from funds received under the Hercules Loan Agreement. The debt issuance costs, the valuation of the warrants, and the final maturity payment of $0.9 million, had been recorded as a debt discount which was being accreted to interest expense through the maturity date of the loan. The remaining unamortized debt discount of $0.2 million and early termination fees were accounted for as a loss on debt extinguishment and included in other income and expense in the statement of operations for the year ended December 31, 2021. Interest expense relating to the loan for three months ended March 31, 2021, was $0.3 million. Interest expense is calculated using the effective interest method and is inclusive of non-cash amortization of the debt discount. At March 31, 2021, the effective interest rate was %. PPP Loan In April 2020, the Company entered into a loan agreement with SVB under the U.S. Small Business Administration (the “SBA”) Paycheck Protection Program (the “PPP”) pursuant to the Coronavirus Aid, Relief and Economic Security Act of 2020 (the “CARES Act”) and received loan proceeds of $0.8 million (the “PPP Loan”). The Company used the loan proceeds for payroll and other covered costs in accordance with the relevant terms and conditions of the CARES Act. The PPP Loan had a maturity date of April 21, 2022 and an interest rate of 1.0% per annum. Under the terms of the PPP, on September 3, 2021, the PPP Loan was forgiven in full, and the Company recognized a gain on extinguishment of debt of $0.8 million. The Company’s scheduled future principal payments for the long-term debt are as follows (in thousands): March 31, 2022 Remainder of 2022 $ — 2023 4,204 2024 6,101 2025 2,195 Total future principal payments 12,500 Less unamortized discount (1,199 ) Carrying value of long-term debt 11,301 Less current portion - Add final fee due at maturity in 2023 819 Long-term portion $ 12,120

Legal and Other Contingencies

Legal and Other Contingencies	3 Months Ended
	Mar. 31, 2022
Commitments And Contingencies Disclosure [Abstract]
Legal and Other Contingencies	7. Legal and Other Contingencies From time to time, the Company may become involved in various lawsuits and legal proceedings, which arise in the ordinary course of business. The Company is currently unaware of any material pending legal proceedings to which it is a party or of which its property is the subject. The Company accounts for its contingent liabilities in accordance with ASC Topic 450, “Contingencies”. Cystic Fibrosis Foundation During 2019, the Company received a funding award (the “2019 CFF Award”) from the Cystic Fibrosis Foundation (“CFF”) and entered into an agreement relating to the award, which agreement was amended in December 2020 providing for an additional award amount. Payment of award amounts are subject to the achievement of certain milestones in connection with the Company’s cystic fibrosis development program. The Company will be required to repay amounts received from the CFF (or specified multiples of such amounts) in certain circumstances, including as royalties on net sales, and, in the event of a disposition of the underlying asset. The funding provided to the Company is accounted for as an advance from a collaboration partner within the scope of ASC Topic 730, “Research and Development.” As of December 31, 2021, the Company received payments of $3.4 million, which are recorded as Advances from collaboration partners in the accompanying condensed consolidated financial statements. In March 2022, the Company entered into an agreement with the CFF to amend the 2019 CFF Award to provide for up to an additional $15.9 million to fund the ongoing global Phase 2 clinical development of ELX-02 in cystic fibrosis (the “2022 CFF Agreement”). The Company received an upfront payment of $7.0 million in March 2022, which was recorded as Advances from collaboration partners in the accompanying condensed consolidated financial statements. The remaining $8.9 million of the amended award may be disbursed to the Company by CFF upon the achievement of certain clinical development milestones. Upon successful commercialization of ELX-02 or any derivative products thereof, the Company will pay the CFF royalties up to 6% of net sales based on the on the actual amount of funding from the CFF. In addition, the 2022 CFF Agreement includes an embedded derivative arising from a provision that upon the occurrence of a change of control or sale or license of funded assets (each a disposition event), the Company would be required to pay the CFF 10% of the consideration received for the disposition event up to three times the amount of funds received from the CFF under the 2022 CFF Agreement. In May 2021, the Company received an additional award from the CFF (the “2021 CFF Award”) to help identify optimized oral RMAs for further development in the treatment of cystic fibrosis patients with nonsense mutations. Payment of award amounts are subject to the achievement of certain milestones in connection with the Company’s oral RMA cystic fibrosis development program. The Company will be required to repay amounts received from the CFF (or specified multiples of such amounts) in certain circumstances, including as royalties on net sales, and, in the event of a disposition of the underlying asset. The funding provided to the Company is accounted for as an advance from a collaboration partner within the scope of ASC Topic 730, “Research and Development.” As of March 31, 2022 and December 31, 2021, the Company received payments of $0.3 million under this award, which are recorded as Advances from collaboration partners in the accompanying condensed consolidated financial statements. The 2021 CFF Award includes an embedded derivative arising from a provision that upon the occurrence of a change of control or sale or license of funded assets (each a disposition event) the Company would be required to pay the CFF 20% of the consideration received for the disposition event up to eight times the amount of funds received from the CFF under the 2021 CFF Agreement. The fair value of the embedded derivatives related to the 2019 CFF Award and the 2021 CFF Award as described above were concluded to be de minimis as of December 31, 2021. In conjunction with the 2022 CFF Agreement, the Company estimated the fair value of the embedded derivatives to be $0.3 million as of March 31, 2022 and has recognized this amount in the condensed consolidated balance sheet as derivative liabilities with the corresponding expense recognized as change in fair value of derivative liabilities in other expense, net, in the condensed consolidated statements of operations for the three months ended March 31, 2022.

Stockholders' Equity

Stockholders' Equity	3 Months Ended
	Mar. 31, 2022
Equity [Abstract]
Stockholders' Equity	8. Stockholders’ Equity Warrants As of March 31, 2022 and December 31, 2021, 323,892 warrants to purchase common stock were outstanding, with a weighted average exercise price of $4.31 per share. The weighted average remaining contractual life at March 31, 2022 was 1.49 years.

Stock-based Compensation

Stock-based Compensation	3 Months Ended
	Mar. 31, 2022
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Stock-based Compensation	9. Stock-based Compensation Summary of Stock Option Activity Transactions related to stock options awarded to employees and directors during the three months ended March 31, 2022 were as follows: Shares Weighted average exercise price Weighted average remaining contractual life (years) Aggregate intrinsic value Options outstanding at December 31, 2021 8,904,444 $ 5.24 7.23 $ 254,223 Granted 3,269,497 0.46 Forfeited (43,161 ) 23.18 Options outstanding at March 31, 2022 12,130,780 $ 3.89 7.76 $ 580,846 Options exercisable at March 31, 2022 2,930,696 $ 10.94 2.69 $ 254,223 The aggregate intrinsic value represents the total intrinsic value (the difference between the fair value of the common stock as of March 31, 2022 and the exercise price, multiplied by the number of in-the-money options) that would have been received by the option holders had all option holders exercised their options on March 31, 2022. This amount is impacted by changes in the fair value of the common stock. Summary of Restricted Stock Unit Activity Activity related to restricted stock units awarded to employees during the three months ended March 31, 2022 were as follows: Shares Weighted average grant date fair value per share Unvested at December 31, 2021 6,263 $ 15.02 Vested (3,131 ) 15.02 Unvested at March 31, 2022 3,132 $ 15.02 Stock-based Compensation Expense Stock-based compensation relates to non-employee directors and non-employees, time-based restricted stock units granted and performance-based stock options and restricted stock units granted . Three Months Ended March 31, 2022 2021 Research and development $ 360 $ 241 General and administrative 562 1,067 Total stock-based compensation expense $ 922 $ 1,308

Fair Value of Financial Instrum

Fair Value of Financial Instruments	3 Months Ended
	Mar. 31, 2022
Fair Value Disclosures [Abstract]
Fair Value of Financial Instruments	10. Fair Value of Financial Instruments At March 31, 2022 and December 31, 2021, the Company’s financial assets valued based on Level 1 inputs consisted of cash and cash equivalents. During the three months ended March 31, 2022, the Company did not have any transfers of financial assets between levels, as defined in Note 2 –Summary of Significant Accounting Policies to the Company’s audited consolidated financial statements as of and for the year ended December 31, 2021 included in the Company’s 2021 Annual Report. Some assets and liabilities are required to be recorded at fair value on a recurring basis, while other assets and liabilities are recorded at fair value on a nonrecurring basis. The carrying amounts of current financial instruments, which include accounts payable, accrued expenses, lease obligation liability and debt, approximate their fair values due to the short-term nature of these instruments. The Company is party to certain funding awards with the Cystic Fibrosis Foundation, which contain embedded derivatives (refer to Note 7). The Company has determined the fair value of these embedded derivatives using a Monte Carlo simulation of the occurrence of a disposition event. The Company has used observable input assumptions such as the amount of funding, the Royalty Cap, as well as unobservable assumptions such as the time to occurrence of 3 years, as well as the probability of occurrence of a disposition event. The table below provides a rollforward of the fair value of the embedded derivatives, a Level 3 fair value estimate (in thousands): Three Months Ended March 31, 2022 Fair value of embedded derivatives, beginning of period $ - Change in fair value of derivative liabilities 270 Fair value of embedded derivatives, end of period $ 270

Other Expense, Net

Other Expense, Net	3 Months Ended
	Mar. 31, 2022
Other Income And Expenses [Abstract]
Other Expense, Net	11. Other Expense, Net Other expense, net consisted of the following (in thousands): Three Months Ended March 31, 2022 2021 Interest and other expense $ 404 $ 260 Interest and other income (14 ) - Foreign currency exchange losses 7 20 Change in fair value of derivative liabilities 270 - Total other expense, net $ 667 $ 280

Net Loss Per Share

Net Loss Per Share	3 Months Ended
	Mar. 31, 2022
Earnings Per Share [Abstract]
Net Loss Per Share	12. Net Loss Per Share The loss and the weighted average number of shares used in computing basic and diluted net loss per share for the periods, are as follows (amounts in thousands, except share and per share data): Three Months Ended March 31, 2022 2021 Numerator: Net loss $ (11,620 ) $ (8,694 ) Denominator: Weighted average number of shares of common stock used in computing net loss per share, basic and diluted 86,651,036 40,180,131 Net loss per share, basic and diluted $ (0.13 ) $ (0.22 ) The following potentially dilutive securities have been excluded from the computation of diluted weighted average shares outstanding as their effect would be anti-dilutive: Three Months Ended March 31, 2022 2021 Options to purchase common stock 12,130,780 4,394,283 Restricted stock units 3,132 268,156 Warrants 323,892 323,892 Total potential common stock equivalents 12,457,804 4,986,331

Basis of Presentation and Sig_2

Basis of Presentation and Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
Recent Accounting Pronouncements	Recent Accounting Pronouncements Although the FASB has issued several ASUs for which adoption dates are pending, the Company does not expect any to have any impacts on its consolidated financial statements.

Prepaid Expenses and Other Cu_2

Prepaid Expenses and Other Current Assets (Tables)	3 Months Ended
	Mar. 31, 2022
Prepaid And Other Current Assets [Abstract]
Prepaid Expenses and Other Current Assets	Prepaid expenses and other current assets consisted of the following (in thousands): March 31, 2022 December 31, 2021 Research and development $ 415 $ 413 Insurance 1,065 123 Other 602 377 Total $ 2,082 $ 913

Property and Equipment (Tables)

Property and Equipment (Tables)	3 Months Ended
	Mar. 31, 2022
Property Plant And Equipment [Abstract]
Property and equipment, net	Property and equipment, net consisted of the following (in thousands): March 31, 2022 December 31, 2021 Computers and software $ 31 $ 31 Office furniture and equipment 27 27 Laboratory equipment 221 221 Leasehold improvements 88 88 Assets in progress 31 20 398 387 Less accumulated depreciation (192 ) (171 ) Property and equipment, net $ 206 $ 216

Accrued Expenses (Tables)

Accrued Expenses (Tables)	3 Months Ended
	Mar. 31, 2022
Payables And Accruals [Abstract]
Accrued expenses	Accrued expenses consisted of the following (in thousands): March 31, 2022 December 31, 2021 Research and development expenses $ 3,374 $ 1,849 Payroll other employee-related expenses 528 1,615 Professional services 380 489 Other 245 141 Interest on debt 104 102 Total $ 4,631 $ 4,196

Debt (Tables)

Debt (Tables)	3 Months Ended
	Mar. 31, 2022
Debt Disclosure [Abstract]
Schedule of Future Principal Payments for Long-Term Debt	The Company’s scheduled future principal payments for the long-term debt are as follows (in thousands): March 31, 2022 Remainder of 2022 $ — 2023 4,204 2024 6,101 2025 2,195 Total future principal payments 12,500 Less unamortized discount (1,199 ) Carrying value of long-term debt 11,301 Less current portion - Add final fee due at maturity in 2023 819 Long-term portion $ 12,120

Stock-based Compensation (Table

Stock-based Compensation (Tables)	3 Months Ended
	Mar. 31, 2022
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Transactions Related to Stock Options Awarded to Employees and Directors	Transactions related to stock options awarded to employees and directors during the three months ended March 31, 2022 were as follows: Shares Weighted average exercise price Weighted average remaining contractual life (years) Aggregate intrinsic value Options outstanding at December 31, 2021 8,904,444 $ 5.24 7.23 $ 254,223 Granted 3,269,497 0.46 Forfeited (43,161 ) 23.18 Options outstanding at March 31, 2022 12,130,780 $ 3.89 7.76 $ 580,846 Options exercisable at March 31, 2022 2,930,696 $ 10.94 2.69 $ 254,223
Activity Related to Restricted Stock Units Awarded to Employees	Activity related to restricted stock units awarded to employees during the three months ended March 31, 2022 were as follows: Shares Weighted average grant date fair value per share Unvested at December 31, 2021 6,263 $ 15.02 Vested (3,131 ) 15.02 Unvested at March 31, 2022 3,132 $ 15.02
Summary of Allocated Stock-based Compensation Expense	Total equity-based compensation expense related to all of the Company’s stock-based awards was recognized as follows (in thousands): Three Months Ended March 31, 2022 2021 Research and development $ 360 $ 241 General and administrative 562 1,067 Total stock-based compensation expense $ 922 $ 1,308

Fair Value of Financial Instr_2

Fair Value of Financial Instruments (Tables)	3 Months Ended
	Mar. 31, 2022
Fair Value Disclosures [Abstract]
Summary of Rollforward of Fair Value of Embedded Derivatives	The table below provides a rollforward of the fair value of the embedded derivatives, a Level 3 fair value estimate (in thousands): Three Months Ended March 31, 2022 Fair value of embedded derivatives, beginning of period $ - Change in fair value of derivative liabilities 270 Fair value of embedded derivatives, end of period $ 270

Other Expense, Net (Tables)

Other Expense, Net (Tables)	3 Months Ended
	Mar. 31, 2022
Other Income And Expenses [Abstract]
Schedule of Other Expense, Net	Other expense, net consisted of the following (in thousands): Three Months Ended March 31, 2022 2021 Interest and other expense $ 404 $ 260 Interest and other income (14 ) - Foreign currency exchange losses 7 20 Change in fair value of derivative liabilities 270 - Total other expense, net $ 667 $ 280

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)	3 Months Ended
	Mar. 31, 2022
Earnings Per Share [Abstract]
Schedule of Loss and Weighted Average Number of Shares Used in Computing Basic and Diluted Net Loss Per Share	The loss and the weighted average number of shares used in computing basic and diluted net loss per share for the periods, are as follows (amounts in thousands, except share and per share data): Three Months Ended March 31, 2022 2021 Numerator: Net loss $ (11,620 ) $ (8,694 ) Denominator: Weighted average number of shares of common stock used in computing net loss per share, basic and diluted 86,651,036 40,180,131 Net loss per share, basic and diluted $ (0.13 ) $ (0.22 )
Potentially Dilutive Securities Excluded from Computation of Diluted Weighted Average Shares Outstanding	The following potentially dilutive securities have been excluded from the computation of diluted weighted average shares outstanding as their effect would be anti-dilutive: Three Months Ended March 31, 2022 2021 Options to purchase common stock 12,130,780 4,394,283 Restricted stock units 3,132 268,156 Warrants 323,892 323,892 Total potential common stock equivalents 12,457,804 4,986,331

Nature of the Business - Additi

Nature of the Business - Additional Information (Detail) - USD ($)	Mar. 31, 2022	Dec. 31, 2021	Sep. 30, 2021
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Accumulated deficit	$ (249,943,000)	$ (238,323,000)
Aggregate principal amount of initial loan advance	11,301,000
Cash, cash equivalents and marketable securities	39,800,000
Hercules Loan Agreement [Member] | Tranche 1 Advance [Member]
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Aggregate principal amount of initial loan advance	12,500,000		$ 12,500,000
Hercules Loan Agreement [Member] | Maximum [Member]
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Aggregate principal amount of initial loan advance	30,000,000		$ 30,000,000
Minimum qualified cash balance	10,000,000
Hercules Loan Agreement [Member] | Minimum [Member]
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Minimum qualified cash balance	$ 6,300,000

Prepaid Expenses and Other Cu_3

Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Detail) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Abstract]
Research and development	$ 415	$ 413
Insurance	1,065	123
Other	602	377
Total	$ 2,082	$ 913

Property and Equipment - Proper

Property and Equipment - Property and Equipment, Net (Detail) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Property, Plant and Equipment [Line Items]
Cost	$ 398	$ 387
Less accumulated depreciation	(192)	(171)
Property and equipment, net	206	216
Computers and software [Member]
Property, Plant and Equipment [Line Items]
Cost	31	31
Office furniture and equipment [Member]
Property, Plant and Equipment [Line Items]
Cost	27	27
Laboratory equipment [Member]
Property, Plant and Equipment [Line Items]
Cost	221	221
Leasehold improvement [Member]
Property, Plant and Equipment [Line Items]
Cost	88	88
Assets in progress [Member]
Property, Plant and Equipment [Line Items]
Cost	$ 31	$ 20

Property and Equipment - Additi

Property and Equipment - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Property Plant And Equipment [Abstract]
Depreciation expenses	$ 21	$ 16

Accrued Expenses - Accrued Expe

Accrued Expenses - Accrued Expenses (Detail) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Payables And Accruals [Abstract]
Research and development expenses	$ 3,374	$ 1,849
Payroll other employee-related expenses	528	1,615
Professional services	380	489
Other	245	141
Interest on debt	104	102
Total	$ 4,631	$ 4,196

Debt - Additional Information (

Debt - Additional Information (Detail)	Sep. 03, 2021USD ($)	Jan. 30, 2019USD ($)	Apr. 30, 2020USD ($)	Mar. 31, 2022USD ($)Installment	Mar. 31, 2021USD ($)	Sep. 30, 2021USD ($)	Dec. 31, 2021USD ($)
Debt Instrument [Line Items]
Aggregate principal amount of initial loan advance				$ 11,301,000
Loan, principal outstanding				12,500,000
Loan, unamortized debt discount				1,199,000
Loan, final maturity payment				$ 819,000
Hercules Loan Agreement [Member]
Debt Instrument [Line Items]
Debt instrument, interest rate terms				Any outstanding principal on the Term Loan Advances will accrue interest at a floating rate equal to the greater of (i) 9.50% per annum and (ii) the sum of 6.25% plus the prime rate, as published in The Wall Street Journal. On September 30, 2021, the interest rate was 9.5%. Interest payments are payable monthly following the funding of a Term Loan Advance.
Debt instrument, payment terms				The Company will be required to make principal payments on the outstanding balance of the Term Loan Advances commencing on April 1, 2023 (the “Term Loan Amortization Date”) in 36 equal monthly instalments, plus interest; provided that if the Company has achieved the milestones described above, then the Term Loan Amortization Date will be automatically extended to October 1, 2023 or April 1, 2024, as applicable.
Loan, floating interest rate				9.50%
Loan, interest rate						9.50%
Loan, frequency of periodic payment				monthly
Loan, number of repayment installments | Installment				36
Loan, periodic principal and interest payment commencement date				Apr. 1, 2023
Loan, maturity date				Apr. 1, 2025
Loan, principal amount percentage				6.55%
Loan, prepayment fee percentage				1.00%
Loan, principal outstanding				$ 12,500,000
Loan, unamortized debt discount				1,200,000
Loan, interest expense				$ 400,000	$ 0
Loan, effective interest rate				15.25%
Loan, final maturity payment				$ 800,000
Hercules Loan Agreement [Member] | Prime Rate [Member]
Debt Instrument [Line Items]
Loan, floating interest rate				6.25%
Hercules Loan Agreement [Member] | Minimum [Member]
Debt Instrument [Line Items]
Loan, prepayment fee percentage				2.00%
Minimum qualified cash balance				$ 6,300,000
Hercules Loan Agreement [Member] | Maximum [Member]
Debt Instrument [Line Items]
Aggregate principal amount of initial loan advance				$ 30,000,000		$ 30,000,000
Loan, prepayment fee percentage				3.00%
Minimum qualified cash balance				$ 10,000,000
Hercules Loan Agreement [Member] | Tranche 1 Advance [Member]
Debt Instrument [Line Items]
Aggregate principal amount of initial loan advance				$ 12,500,000		12,500,000
Hercules Loan Agreement [Member] | Tranche 2 Advance [Member]
Debt Instrument [Line Items]
Aggregate principal amount of initial loan advance						7,500,000
Hercules Loan Agreement [Member] | Tranche 3 Advance [Member]
Debt Instrument [Line Items]
Aggregate principal amount of initial loan advance						10,000,000
Loan Agreement [Member]
Debt Instrument [Line Items]
Debt instrument, interest rate terms		Outstanding principal on the loan accrues interest at a floating rate equal to the greater of (i) 5.25% per annum and (ii) the sum of 2.5% plus the prime rate, as published in the Wall Street Journal. Interest payments are payable monthly.
Loan, floating interest rate		5.25%
Loan, interest rate					5.75%
Loan, principal outstanding						6,700,000
Loan, unamortized debt discount							$ 200,000
Loan, interest expense					$ 300,000
Loan, effective interest rate					10.85%
Loan, final maturity payment						900,000
Gain (loss) on extinguishment of debt						$ 100,000
Loan Agreement [Member] | Prime Rate [Member]
Debt Instrument [Line Items]
Loan, floating interest rate		2.50%
Loan Agreement [Member] | Initial Loan [Member]
Debt Instrument [Line Items]
Aggregate principal amount of initial loan advance		$ 15,000,000
Loan Agreement [Member] | PPP Loan [Member]
Debt Instrument [Line Items]
Loan, maturity date			Apr. 21, 2022
Gain (loss) on extinguishment of debt	$ 800,000
PPP Loan proceeds received			$ 800,000
Promissory note interest rate			1.00%

Debt - Schedule of Future Princ

Debt - Schedule of Future Principal Payments for Long-Term Debt (Detail) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Debt Disclosure [Abstract]
2023	$ 4,204
2024	6,101
2025	2,195
Total future principal payments	12,500
Less unamortized discount	(1,199)
Carrying value of long-term debt	11,301
Add final fee due at maturity in 2023	819
Long-term debt	$ 12,120	$ 11,996

Legal and Other Contingencies -

Legal and Other Contingencies - Additional Information (Detail) $ in Thousands	3 Months Ended
	Mar. 31, 2022USD ($)Time	Dec. 31, 2021USD ($)
Legal And Other Contingencies [Line Items]
Advances from collaboration partners	$ 10,723	$ 3,723
2019 CFF Award [Member]
Legal And Other Contingencies [Line Items]
Advances from collaboration partners		3,400
2021 CFF Award [Member]
Legal And Other Contingencies [Line Items]
Advances from collaboration partners	$ 300	$ 300
2021 CFF Award [Member] | Cystic Fibrosis Foundation [Member]
Legal And Other Contingencies [Line Items]
Percentage of consideration received for disposition event	20.00%
Number of times amount of funds received | Time	8
2022 CFF Agreement [Member] | Cystic Fibrosis Foundation [Member]
Legal And Other Contingencies [Line Items]
Royalties percentage of net sales based on actual amount of funding	6.00%
Percentage of consideration received for disposition event	10.00%
Number of times amount of funds received | Time	3
2022 CFF Agreement [Member] | Cystic Fibrosis Foundation [Member] | Phase 2 Clinical Development [Member]
Legal And Other Contingencies [Line Items]
Upfront payment received	$ 7,000
Remaining amount of award payable upon achievement certain clinical development milestones	8,900
2022 CFF Agreement [Member] | Cystic Fibrosis Foundation [Member] | Phase 2 Clinical Development [Member] | Maximum [Member]
Legal And Other Contingencies [Line Items]
Award to fund development milestones	15,900
2022 CFF Agreement [Member] | Liabilities [Member]
Legal And Other Contingencies [Line Items]
Advances from collaboration partners	$ 300

Stockholder's Equity - Addition

Stockholder's Equity - Additional Information (Detail) - $ / shares	3 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Stockholders Equity [Abstract]
Number of common stock in warrant	323,892	323,892
Weighted average exercise price	$ 4.31	$ 4.31
Weighted average remaining contractual life	1 year 5 months 26 days

Stock-based Compensation - Tran

Stock-based Compensation - Transactions Related to Stock Options Awarded to Employees and Directors (Detail) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Amount
Options outstanding at December 31, 2021	8,904,444
Granted	3,269,497
Forfeited	(43,161)
Options outstanding at March 31, 2022	12,130,780	8,904,444
Options exercisable at March 31, 2022	2,930,696
Weighted average exercise price
Options outstanding at December 31, 2021	$ 5.24
Granted	0.46
Forfeited	23.18
Options outstanding at March 31, 2022	3.89	$ 5.24
Options exercisable at March 31, 2022	$ 10.94
Weighted average remaining contractual life
Options outstanding	7 years 9 months 3 days	7 years 2 months 23 days
Options exercisable	2 years 8 months 8 days
Aggregate intrinsic value
Options outstanding	$ 580,846	$ 254,223
Options exercisable	$ 254,223

Stock-based Compensation - Acti

Stock-based Compensation - Activity Related to Restricted Stock Units Awarded to Employees (Detail) - Restricted Stock Units [Member]	3 Months Ended
	Mar. 31, 2022$ / sharesshares
Amount
Unvested at December 31, 2021 | shares	6,263
Vested | shares	(3,131)
Unvested at March 31, 2022 | shares	3,132
Weighted average grant date fair value price
Unvested at December 31, 2021 | $ / shares	$ 15.02
Vested | $ / shares	15.02
Unvested at March 31, 2022 | $ / shares	$ 15.02

Stock-based Compensation - Summ

Stock-based Compensation - Summary of Allocated Stock-based Compensation Expense (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation expense	$ 922	$ 1,308
Research and Development Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation expense	360	241
General and Administrative Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation expense	$ 562	$ 1,067

Fair Value of Financial Instr_3

Fair Value of Financial Instruments - Additional Information (Detail)	3 Months Ended
	Mar. 31, 2022
Fair Value Disclosures [Abstract]
Transfers of financial assets between level 2 and level 3	the Company did not have any transfers of financial assets between levels
Fair value of unobservable assumptions period	3 years

Fair Value of Financial Instr_4

Fair Value of Financial Instruments - Summary of Rollforward of Fair Value of Embedded Derivatives (Detail) $ in Thousands	3 Months Ended
	Mar. 31, 2022USD ($)
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Change in fair value of derivative liabilities	$ 270
Monte Carlo Simulation [Member] | Level 3 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Change in fair value of derivative liabilities	270
Fair value of embedded derivatives, end of period	$ 270

Other Expense, Net - Schedule o

Other Expense, Net - Schedule of Other Expense, Net (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Other Income And Expenses [Abstract]
Interest and other expense	$ 404	$ 260
Interest and other income	(14)
Foreign currency exchange losses	7	20
Change in fair value of derivative liabilities	270
Total other expense, net	$ 667	$ 280

Net Loss Per Share - Schedule o

Net Loss Per Share - Schedule of Loss and Weighted Average Number of Shares Used in Computing Basic and Diluted Net Loss Per Share (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Numerator:
Net loss	$ (11,620)	$ (8,694)
Denominator:
Weighted average number of shares of common stock used in computing net loss per share, basic and diluted	86,651,036	40,180,131
Net loss per share, basic and diluted	$ (0.13)	$ (0.22)

Net Loss Per Share - Potentiall

Net Loss Per Share - Potentially Dilutive Securities Excluded from Computation of Diluted Weighted Average Shares Outstanding (Detail) - shares	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Total potential common stock equivalents	12,457,804	4,986,331
Options to Purchase Common Stock [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Total potential common stock equivalents	12,130,780	4,394,283
Restricted Stock Units [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Total potential common stock equivalents	3,132	268,156
Warrants [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Total potential common stock equivalents	323,892	323,892